34 results about "Inhalation preparations" patented technology

The invention relates to a riociguat prodrug as shown in a formula X or pharmaceutically acceptable salt thereof, a preparation method, an intermediate and a pharmaceutical composition thereof. The prodrug takes amino of riociguat as a modification site and is connected through an ester carrier, drug release is triggered by utilizing lung amidase, and lung targeted delivery is realized by adjusting a lipid-water partition coefficient. Pharmacokinetic studies show that the prodrug can significantly improve the drug concentration and total exposure of the lung, reduce the blood concentration of the whole body, and show excellent lung targeting characteristics. The invention also provides a pharmaceutical composition (preferably an inhalation preparation) containing the prodrug, and an application of the prodrug in preparation of drugs for preventing, treating, treating or relieving pulmonary arterial hypertension of patients. .

There is provided inhalable formulations of ruxolitinib, manufacture, and uses thereof.

The present invention relates to inhalable formulations, and kits and methods suitable for the preparation of such inhalable formulations. The inhalable formulations comprise a freebase of a deuterium-substituted dimethyltryptamine compound. The inhalable formulations also comprise a biocompatible excipient. Such formulations are suitable for inhalation and have uses in the treatment of psychiatric or neurological disorders. Deuterium-substituted dimethyltryptamine compounds may be metabolised more slowly than their protio analogues, allowing for a longer lasting therapeutic effect.

The application relates to the technical field of pharmaceutical preparation mixing processes, in particular to a stirring device and a high-speed centrifugal device adopting the stirring device, which comprises a stirring paddle and a directional rotor, the stirring paddle and the directional rotor are coaxially and oppositely arranged, and are used for providing opposite shearing forces when rotating. Compared with the prior art, the application has the advantages that when two or more materials with large particle size difference and large proportion difference are mixed, the materials can reach a uniform and stable state in a short time under the action of high shearing force, the RSD value of content detection of random sampling in the tank is at a low level, and the mixed materials can meet the tanking requirements of powder for inhalation preparations.

The invention belongs to the technical field of veterinary traditional Chinese medicine preparations, and particularly relates to a veterinary traditional Chinese medicine compound aerosol inhalation preparation which is prepared from traditional Chinese medicines with the effects of clearing away heat and toxic materials, ventilating the lung, relieving cough, relieving sore throat and diminishing swelling as raw materials through scientific compatibility and a specific process. The raw material medicines comprise, by weight, 15-30 parts of honeysuckle, 12-25 parts of fructus forsythiae, 10-20 parts of radix isatidis, 8-18 parts of platycodon grandiflorum, 6-15 parts of mint, 5-12 parts of liquorice, 6-14 parts of almond, 8-16 parts of folium mori, 10-22 parts of chrysanthemum and 8-18 parts of scutellaria baicalensis; the requirements of the raw material medicines are as follows: the honeysuckle is a dry flower bud or a flower with initial blooming of a honeysuckle plant, and is dried at low temperature, and the water content is 8-12%; the traditional Chinese medicine composition is prepared from traditional Chinese medicines with the effects of clearing away heat and toxic materials, ventilating the lung, relieving cough, relieving sore throat and diminishing swelling as raw materials through scientific compatibility and a specific process, has the advantages of high targeting property, quick response, definite curative effect, small toxic and side effects, difficulty in drug resistance generation and the like, is excellent in atomization performance, is suitable for group administration, and can effectively solve the problem of prevention and treatment of respiratory diseases of livestock and poultry.

The invention relates to preparations for inhalation and to methods for preventing or treating equine asthma in horses, wherein the preparation contains a vasoactive intestinal peptide (VIP) receptor agonist, in particular aviptadil.

A pressurized inhalation composition includes tiotropium or its pharmaceutically acceptable salt thereof, ethanol, a stabilizer, and a propellant. The ethanol can be in an amount of from about 1% (w / w) to about 10% (w / w) based on the total weight of the pressurized inhalation composition. The composition can be pharmacokinetically bioequivalent to non-pressurized aqueous base inhalation formulation of tiotropium. An inhaler can include the composition contained in a canister fitted with metering valve, and an actuator optionally connected with a dose counter. A process of preparing the pressurized inhalation composition and using the pressurized inhalation composition in the treatment of Asthma and Chronic obstructive pulmonary disease (COPD) in a patient in need thereof by inhalation administration are also described.

The invention belongs to the technical field of inhalation preparations and pulmonary drug delivery, and particularly relates to an atomization preparation for vitamin K inhalation drug delivery and preparation and application thereof. According to the preparation, dipalmitoyl phosphatidylcholine, cholesterol and optional anionic phospholipid are adopted to construct a bionic lung surface activity liposome skeleton LA1, an MK-7 organic phase is intercalated into a liposome double-layer hydrophobic area under the condition of controlling temperature and an energy path, and a continuous phase containing sodium chloride, propylene glycol and a pH regulator is matched to form an isotonic near-neutral environment; a neutral oil phase, a fat-soluble antioxidant, an optional metal chelating agent and a viscosity modifier can be introduced to synergistically optimize the atomization performance. The apparent viscosity of the prepared atomization preparation at 25 DEG C is 1.0-2.5 mPa.s, the osmotic pressure is 280-320 mOsm / kg, the average particle size of lipidosome Z is 80-150 nm, the PDI is not larger than 0.25, the mass median diameter of fog drops atomized by a vibration net type atomizer is 2.0-3.0 microns, the fine particle fraction is not smaller than 60%, and the MK-7 content retention rate is not lower than 90% after 6 months of accelerated storage at 25-40 DEG C.

The invention relates to the technical field of inhalation preparations, in particular to an inhalation preparation for relieving or treating upper respiratory tract infection and a preparation method and application thereof. The inhalation preparation comprises an active pharmaceutical ingredient, and the active pharmaceutical ingredient is andrographolide; the inhalation preparation also comprises pharmaceutically acceptable auxiliary materials; the pharmaceutically acceptable auxiliary materials comprise one or more of a solvent, a cosolvent, a propellant, a carrier / diluent, a pH regulator, an antistatic agent and a stabilizer. The prescriptions and the preparation methods of the aerosol, the dry powder inhalation and the spray are suitable for industrial production, and clinical tests prove that the prepared inhalation preparation has a remarkable relieving or treating effect on upper respiratory tract infection.

There is provided inhalable formulations of ruxolitinib, manufacture, and uses thereof.

The invention discloses a medicinal composition of a triple compound inhalation preparation as well as a preparation method and application of the medicinal composition, and relates to the technical field of respiratory system medicinal preparations. According to the pharmaceutical composition, the pharmaceutical composition which is convenient to use and better in effect can be obtained by compounding the ingredients of the pharmaceutical composition, the problem of non-uniform mixing of the ingredients with high dose difference is solved through a step-by-step mixing process, the powder flowability is ensured, the lung delivery efficiency is improved, and the pharmaceutical composition is suitable for clinical application. The medicine can be suitable for maintenance treatment of asthma or chronic obstructive pulmonary disease, and can also prevent acute exacerbation of chronic obstructive pulmonary disease and / or improve the symptom severity of acute exacerbation of chronic obstructive pulmonary disease.

A pressurized inhalation composition includes tiotropium or its pharmaceutically acceptable salt thereof, ethanol, a stabilizer, and a propellant. The ethanol can be in an amount of from about 1% (w / w) to about 10% (w / w) based on the total weight of the pressurized inhalation composition. The composition can be pharmacokinetically bioequivalent to non-pressurized aqueous base inhalation formulation of tiotropium. An inhaler can include the composition contained in a canister fitted with metering valve, and an actuator optionally connected with a dose counter. A process of preparing the pressurized inhalation composition and using the pressurized inhalation composition in the treatment of Asthma and Chronic obstructive pulmonary disease (COPD) in a patient in need thereof by inhalation administration are also described.

This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

The application discloses a compound polymyxin inhalation preparation, which is composed of a polymyxin polypeptide, an aminoglycoside antibiotic and a pharmaceutically acceptable auxiliary material. The molar ratio of the polymyxin polypeptide to the aminoglycoside antibiotic in the inhalation preparation is 1:20-1:80. Compared with single preparation or a compound preparation with a molar ratio of less than 1:20, the compound preparation with the molar ratio can significantly reduce lung toxicity and achieve a significant effect of clearing multiple drug-resistant bacteria in lung infection. The compound drug is delivered by using an inhalation liquid preparation dosage form, so that the total drug delivery efficiency of atomization inhalation is greatly improved, the median particle size of the drug is smaller, and the proportion of particles with a size of less than 5 microns is more than 55%, so that the drug is more easily inhaled into the lung to achieve an anti-infection treatment effect.

This invention discloses a QL-H008 formulation for treating gliomas, its preparation method, and its application, and also discloses the application of compound QL-H008 in the preparation of drugs for treating gliomas. This invention utilizes an oral-nasal inhalation formulation, inhaling an aerosol containing QL-H008 and pharmaceutically acceptable salts through the mouth and nose to achieve the therapeutic effect on gliomas in situ, demonstrating the promising application of QL-H008 in the treatment of gliomas in situ.

The invention discloses an inhalation preparation for treating IPF diseases. The inhalation preparation is an aerosol inhalation liquid preparation, an inhalation aerosol, an inhalation powder aerosol or a soft aerosol. The inhalation preparation comprises an active drug, and the active drug is any one of apremilast, ibudilast, roflumilast, crisaborole and defamilast. A preparation process of an inhalation preparation is introduced into a traditional preparation, active ingredients of a traditional oral preparation are easily damaged in digestive tracts, the bioavailability is low, the liver first-pass effect is achieved, the effect is slow, and the inhalation preparation capable of remarkably improving IPF is prepared. Tests prove that the prepared inhalation preparation can effectively improve the bioavailability and improve the clinical use effect.

This invention relates to a method of treatment of asthma comprising a pro re nata (PRN) administration of a fixed-dose dry powder inhalation composition comprising fluticasone propionate and albuterol sulfate as a rescue medication in patients, wherein the fluticasone propionate is administered at a delivered dose of 22-59 mcg per inhalation and the albuterol sulfate is administered at a delivered dose of 92-124 mcg per inhalation, and wherein the treatment provides an improved baseline-adjusted postdose forced expiratory volume in one second (FEV1) area under the effect curve from time zero to 6 hours (AUEC0-6h) when compared to fluticasone propionate treatment and an improved baseline-adjusted trough FEV1 when compared to albuterol sulfate treatment.

An inhalation formulation for treating an IPF disease. The inhalation formulation is an aerosol inhalation liquid formulation, an inhalation aerosol, a dry powder inhaler or a soft mist inhaler. The inhalation formulation contains an active drug, and the active drug is any one of apremilast, ibudilast, roflumilast, crisaborole, and difamilast. A preparation process for the inhalation formulation is introduced into a conventional formulation. An active component in a conventional oral formulation is prone to being destroyed in the digestive tract, and has low bioavailability, a liver first pass effect, and a slow onset of action. An inhalation formulation capable of significantly alleviating IPF is prepared. Tests prove that the prepared inhalation formulation can effectively increase the bioavailability, and improve the clinical use effect.

The invention discloses a lung protection function exosome based on resveratrol-astragalus membranaceus-ginseng induction, an inhalation preparation and application, and belongs to the technical field of biology. The exosome is obtained by inducing lung fibroblasts by active ingredients containing resveratrol, an astragalus extract and a ginseng extract and then secreting the lung fibroblasts; wherein the content of astragaloside in the astragalus extract is not less than 2.0%, and the total content of ginsenoside Rg1 and Rb1 in the ginseng extract is not less than 5.0%. The invention also provides a dry powder inhalant or an aerosol inhalation solution containing the exosome. The exosome and the preparation thereof play a lung protection role through multiple mechanisms such as inflammation regulation and control, oxidative stress resistance and repair promotion, can be used for preventing and / or treating various lung injury diseases such as acute lung injury and pneumonia, and have the advantages of good biocompatibility and strong targeting property.

Disclosed is a pharmaceutical composition containing Fudosteine, comprising the following components: a pharmaceutically active ingredient, a pH adjuster, and water. The concentration of Fudosteine in the composition ranges from 20 mg / mL to 200 mg / mL, and the pH value is between 3.0 and 6.0. The pharmaceutically active ingredient is one or more of Fudosteine, a pharmaceutically acceptable salt thereof, and a hydrate thereof. The pharmaceutical composition containing Fudosteine does not comprise an antioxidant, a surfactant, and a metal chelating agent, and can be prepared into an atomized inhalation preparation.

The present invention relates to a method of treating asthma comprising administering as rescue medication a fixed-dose dry powder inhalation composition comprising fluticasone propionate and salbutamol sulfate in patients aged > 4 years on an as-needed (PRN) basis, wherein the fluticasone propionate is administered at a delivered dose of 22-59 micrograms per inhalation, the salbutamol sulfate is administered at a delivered dose of 92-124 micrograms per inhalation, and the treatment provides one or more of: an extended time to first severe clinical asthma exacerbation compared to salbutamol sulfate rescue treatment, a reduced total annualized systemic corticosteroid (SCS) exposure compared to salbutamol sulfate rescue treatment, a reduced annualized rate of severe clinical asthma exacerbations compared to salbutamol sulfate rescue treatment. Also provided is a fixed-dose dry powder inhalation composition and a dry powder inhaler for use in performing the method of the invention.

The utility model belongs to the technical field of airtightness testing, and particularly discloses an inhalation preparation airtightness testing tool which comprises a shell and a gland fixed above the shell. A circular groove is formed in the upper surface of the shell, a first sealing ring is arranged on the inner side of the circular groove, a lower cavity is formed below the circular groove, an inhalation preparation bottle body is arranged in the lower cavity, an inhalation preparation atomization device is arranged above the inhalation preparation bottle body, a through hole is formed in the middle of the gland, and the inhalation preparation atomization device penetrates through the through hole and the first sealing ring. A second sealing ring is arranged between the inhalation preparation bottle body and the inhalation preparation atomization device, the structural design is optimized, the split type gland is adopted to be matched with the lower cavity, and the double sealing rings are combined to isolate the leakage risk of the inhalation preparation atomization device and the inhalation preparation bottle body, so that the sealing performance of the bottle body is accurately detected, and the sealing performance of the inhalation preparation atomization device and the inhalation preparation bottle body is improved. The split type gland and locking screw design is adopted, the sealing pressure can be adjusted conveniently, and the sealing reliability is ensured.

The utility model relates to the technical field of respiratory medicine physiological research, and discloses a respiratory tract deposition distribution testing device for inhalation preparations, which comprises a respiratory tract model unit, a head model and a respiratory tract model unit, the respiratory tract model unit comprises a sealed container, a pulmonary trachea model and a head model, and the air inlet end of the pulmonary trachea model extends to the outside of the sealed container; the head model is connected with the air inlet end of the pulmonary trachea model; the breathing machine system comprises a breathing machine, a connecting pipeline and a medicine feeding device, and the end, away from the breathing machine, of the connecting pipeline is connected to the mouth and / or the nose of the head model; and the air bag unit comprises a filtering assembly and an air bag assembly, the filtering assembly is connected with the sealed container, and the air bag assembly comprises an air bag which adaptively expands and contracts when the breathing machine system works. Under the condition that a breathing machine system assists ventilation, the respiratory tract model adapts to running parameters of the breathing machine, the function that a real bionic breathing machine assists human body breathing is achieved, and the deposition result of drug particles in the respiratory tract is accurately simulated.

The present invention relates to a method of treating asthma, said method comprising the treatment of asthma at an age of > = 4 years to lt; a fixed dose of a dry powder inhalation composition comprising fluticasone propionate and salbutamol sulfate is administered as an emergency drug on demand (PRN) for a 18-year-old patient. Fixed dose dry powder inhalation compositions and dry powder inhalers for performing the methods of the invention are also provided.

The application discloses a kind of compound pharmaceutical composition containing PDE-3 / 4 inhibitor, pharmaceutical preparation and preparation method and application thereof, belong to medical technology field.For the high adverse reaction risk of existing COPD treatment drug, poor patient compliance, heavy economic burden, lack of compound inhalation preparation suitable for severe patients;And the physicochemical properties of different active ingredients are greatly different, it is difficult to stably disperse, PDE-3 / 4 inhibitor wet heat sterilization is easy to generate impurities and other problems.The composition of the application includes PDE-3 / 4 inhibitor, glucocorticoid / JAK inhibitor anti-inflammatory component and LABA / LAMA long-acting bronchodilator.Using polysorbate 80-hydroxypropyl betacyclodextrin stabilizing system, the wet heat sterilization process is optimized, the sterilization concentration is controlled to be 100mg / mL, the process impurities are greatly reduced, the product purity and safety are improved, and sterile inhalation suspension is prepared, which can be atomized to treat chronic bronchitis related COPD.

A pressurized inhalation composition includes tiotropium or its pharmaceutically acceptable salt thereof, ethanol, a stabilizer, and a propellant. The ethanol can be in an amount of from about 1% (w / w) to about 10% (w / w) based on the total weight of the pressurized inhalation composition. The composition can be pharmacokinetically bioequivalent to non- pressurized aqueous base inhalation formulation of tiotropium. An inhaler can include the composition contained in a canister fitted with metering valve, and an actuator optionally connected with a dose counter. A process of preparing the pressurized inhalation composition and using the pressurized inhalation composition in the treatment of Asthma and Chronic obstructive pulmonary disease (COPD) in a patient in need thereof by inhalation administration are also described.

The present disclosure provides compounds of Formula (I), Formula (la), or Formula (lb), or their pharmaceutically acceptable salts and aqueous solvent-containing pharmaceutical formulations. These pharmaceutical formulations of the present disclosure are useful for treating and preventing viral infections in a subject in need thereof, and are for administration by inhalation.

The invention discloses a linezolid liposome inhalation preparation and a preparation method thereof, and the linezolid liposome inhalation preparation is prepared by dissolving linezolid, phospholipid and cholesterol in an organic phase, then removing an organic solvent through a film dispersion method, adding a 0.9% sodium chloride solution for hydration, and finally homogenizing to obtain the linezolid liposome inhalation preparation. Meanwhile, compared with a linezolid injection, entrapment of the liposome on the linezolid can enable the linezolid to act on the outer membrane of bacteria more accurately and generate an inhibiting or damaging effect on the outer membrane of the bacteria, so that gram-positive bacteria are effectively killed, meanwhile, an inhalation administration mode is adopted, the administration dosage of the medicine is reduced, and the bioavailability of the medicine is improved. The adverse reaction caused by systemic administration is reduced, and meanwhile, the compliance of a patient is improved.

An inhalation preparation for treating pulmonary edema, comprising a pyridine sulfonamide phosphate compound represented by formula 1 or a pharmaceutically acceptable salt thereof and a cationic guar gum. The cationic guar gum can greatly improve the permeability of the pyridine sulfonamide phosphate compound or the pharmaceutically acceptable salt thereof in a Calu-3 cell model (an in vitro simulation of lung tissue epithelial cell model). The application also provides a preparation method of the inhalation preparation: under normal temperature and pressure, the main drug, the absorption promoter and the freeze-drying excipient are dissolved in water in proportion and are constant volume to the total amount, and are filtered and freeze-dried. The inhalation preparation prepared by the application has strong lung permeability, simple production process and good application prospect.